Theratechnologies (NASDAQ:THTX) Trading 0.9% Higher – Still a Buy?

Theratechnologies Inc. (NASDAQ:THTX) traded up 0.9% on Tuesday . The stock traded as high as $3.40 and last traded at $3.42. 3,272,872 shares were traded during mid-day trading, an increase of 345% from the average session volume of 735,945 shares. The stock had previously closed at $3.39.

Analyst Ratings Changes

THTX has been the subject of several analyst reports. Jones Trading downgraded Theratechnologies from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Theratechnologies in a report on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold”.

Theratechnologies Price Performance

The firm has a fifty day moving average price of $3.28 and a 200-day moving average price of $2.78. The company has a market capitalization of $157.21 million, a P/E ratio of -17.99 and a beta of 0.51.

Theratechnologies (NASDAQ:THTX) last posted its quarterly earnings data on Wednesday, July 9th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.08). The business had revenue of $17.73 million during the quarter, compared to analyst estimates of $24.30 million. On average, research analysts forecast that Theratechnologies Inc. will post 0.01 EPS for the current year.

Institutional Trading of Theratechnologies

Large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its holdings in Theratechnologies by 1,416.7% during the fourth quarter. Bank of America Corp DE now owns 16,487 shares of the company’s stock worth $30,000 after buying an additional 15,400 shares during the last quarter. TD Waterhouse Canada Inc. grew its position in shares of Theratechnologies by 63.4% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 18,038 shares of the company’s stock valued at $41,000 after acquiring an additional 7,000 shares during the period. Stonepine Capital Management LLC bought a new position in shares of Theratechnologies during the 1st quarter valued at approximately $36,000. Acadian Asset Management LLC purchased a new position in Theratechnologies in the first quarter valued at approximately $39,000. Finally, Cyndeo Wealth Partners LLC purchased a new position in Theratechnologies in the first quarter valued at approximately $42,000.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.